While vitamin C is essential for health, high doses can cause serious side effects. Learn the risks and how to use it safely, based on research.

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, Baystreet.ca News Commentary, The global oncology and cancer drugs market, valued at $167 billion in 2023, is projected to reach $335.2 billion ...

US FDA approves AstraZeneca’s Calquence plus venetoclax as first all-oral, fixed-duration combination for patients with CLL in the 1st-line setting: Cambridge, UK Monday, Februa ...

First and only all-oral, fixed-duration regimen designed to provide CLL patients with the potential to experience time off treatment –– Approval expands Genentech’s fixed-duration portfolio by ...

First all-oral, fixed-duration combination regimen approved for previously untreated patients with CLL Approval supported by data from the Phase 3 AMPLIFY ...

Expert breaks down CLL frontline choices, IGHV and p53 risk, and what fits patient life. The treatment landscape for chronic ...

Leukemic ocular involvement arises from direct infiltration, hematologic derangements (anemia, thrombocytopenia, ...

BeOne Medicines AG (NASDAQ:ONC) is one of the High Growth International Stocks to Buy Now. On February 9, Rebecca Liang from Bernstein reiterated a Buy rating on the stock with a $414 price target.

Margaret Krackeler, MD, of Kaiser Permanente Northern California, shares lessons on implementing evidence-based formulary changes for patients with CLL.

The researchers conducted a retrospective analysis of costs associated with hospitalization of CLL patients with serious infections.

Although prognostic significance of 1q21 chromosomal abnormalities (CAs) in multiple myeloma (MM) has been validated, the real world data (RWD) of its practical utilization in the clinical practice ...

Javascript must be enabled to use this site. Please enable Javascript in your browser and try again. Use AARP’s interactive scam-tracking map to stay informed about ...